Studies have shown that the combination of LAG-3 and MHC-II contributes to avoiding apoptosis of tumour cells and promoting tumour-specific CD4+ T-cell recruitment but reduces the response of CD8+ T cells (7, 13, 23–27). This evidence concerns the gene LAG3 and neoplasm.